Hypothesis

Enhanced activation of the mitochondrial unfolded protein response (UPRmt) in peripheral sensory neurons increases Humanin secretion, which dampens nociceptor excitability and slows epigenetic aging. Conversely, chronic integrated stress response (ISR) activation suppresses UPRmt‑driven Humanin, lowering pain threshold and accelerating biological age.

Mechanistic Rationale

Mitochondrial retrograde signaling via UPRmt relies on ATF5 and CHOP to transcriptionally upregulate cytoprotective peptides, including Humanin. Humanin can act on neuronal GPCRs (e.g., GPRC12) to reduce intracellular calcium and inhibit TRPV1 sensitization, directly raising heat pain threshold. ISR, triggered by eIF2α phosphorylation, antagonizes ATF5 signaling and shifts the balance toward pro‑inflammatory transcripts that sensitize nociceptors. Humanin levels decline with age in plasma, yet centenarian offspring retain higher concentrations, correlating with better healthspan. No study has examined whether manipulating UPRmt or ISR specifically in dorsal root ganglion (DRG) neurons alters Humanin release, pain sensitivity, and epigenetic clocks in tandem.

Testable Predictions

1. Genetic or pharmacologic boosting of UPRmt in Nav1.8+ DRG neurons will increase plasma Humanin, raise heat pain threshold, and decelerate Horvath epigenetic age acceleration in mice.
2. Selective ISR activation (e.g., via PERK agonist) in the same neurons will reduce Humanin, lower pain threshold, and accelerate epigenetic age.
3. Exogenous Humanin rescue will normalize pain sensitivity and epigenetic age in ISR‑activated mice without affecting UPRmt markers.
4. In humans, polymorphisms linked to higher ATF5 activity in sensory neurons will associate with higher pain tolerance and lower epigenetic age acceleration independent of chronological age.

Experimental Approach

• Generate Nav1.8‑Cre; ATF5^fl/fl (UPRmt loss) and Nav1.8‑Cre; ATF5^OE (overexpression) mouse lines. Measure baseline and capsaicin‑induced heat pain thresholds via Hargreaves test.
• Collect plasma for Humanin ELISA and perform DRG RNA‑seq to confirm UPRmt/ISR pathway engagement.
• Extract blood DNA for Horvath and Hannum epigenetic clocks at 3, 6, 12 months.
• Pharmacologic arms: treat wild‑type mice with ISR inhibitor (GSK2606414) or Humanin peptide (1 mg/kg i.p. daily) and repeat pain and epigenetic assessments.
• Human validation: genotype ATF5 promoter SNPs in a cohort of 500 adults, assess pressure pain tolerance, and compute epigenetic age from blood methylation.

Potential Outcomes and Interpretation

If UPRmt elevation raises Humanin, increases pain threshold, and slows epigenetic aging, the hypothesis gains mechanistic support, positioning sensory neuron mitochondrial signaling as a bridge between subjective pain experience and biological age. Failure to observe coordinated changes would falsify the claim that UPRmt‑Humanin directly links nociception to epigenetic age, suggesting that pain‑age correlations arise from systemic confounders rather than neuron‑autonomous mitochondrial retrograde signaling.

This framework transforms a speculative correlation into a falsifiable, pathway‑driven model that can be tested with existing genetic tools, pharmacological agents, and epigenetic clocks, offering a clear route to validate or refute the idea that pain tolerance proxies biological age via mitochondrial‑Humanin signaling in sensory neurons.